{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T21:17:40Z","timestamp":1789593460197,"version":"build-2803163510"},"reference-count":50,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinics in Laboratory Medicine"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1016\/j.cll.2013.11.003","type":"journal-article","created":{"date-parts":[[2014,1,14]],"date-time":"2014-01-14T10:17:09Z","timestamp":1389694629000},"page":"113-127","source":"Crossref","is-referenced-by-count":24,"title":["Cholesterol, Lipoproteins, High-sensitivity C-reactive Protein, and Other Risk Factors for Atherosclerosis"],"prefix":"10.1016","volume":"34","author":[{"given":"Joseph","family":"Rudolf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kent B.","family":"Lewandrowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.cll.2013.11.003_bib1","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1161\/CIR.0b013e31823ac046","article-title":"Heart disease and stroke statistics\u20132012 update: a report from the American Heart Association","volume":"125","author":"Roger","year":"2012","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.cll.2013.11.003_bib2","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1161\/CIRCULATIONAHA.109.192703","article-title":"Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association's strategic impact goal through 2020 and beyond","volume":"121","author":"Lloyd-Jones","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.cll.2013.11.003_bib3","series-title":"Robbins and Cotran pathologic basis of disease","author":"Kumar","year":"2010"},{"issue":"2","key":"10.1016\/j.cll.2013.11.003_bib4","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJM199901143400207","article-title":"Atherosclerosis\u2013an inflammatory disease","volume":"340","author":"Ross","year":"1999","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cll.2013.11.003_bib5","series-title":"Clinical chemistry: laboratory management and clinical correlations","first-page":"575","article-title":"Lipids, lipoproteins, and cardiovascular risk","author":"\u00c1bel","year":"2002"},{"issue":"7","key":"10.1016\/j.cll.2013.11.003_bib6","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1515\/cclm-2011-0636","article-title":"Laboratory approaches for predicting and managing the risk of cardiovascular disease: postanalytical opportunities of lipid and lipoprotein testing","volume":"50","author":"Langlois","year":"2012","journal-title":"Clin Chem Lab Med"},{"issue":"12","key":"10.1016\/j.cll.2013.11.003_bib7","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1056\/NEJMcp044370","article-title":"Clinical practice. Low HDL cholesterol levels","volume":"353","author":"Ashen","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"25","key":"10.1016\/j.cll.2013.11.003_bib8","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","article-title":"Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report","volume":"106","year":"2002","journal-title":"Circulation"},{"issue":"15","key":"10.1016\/j.cll.2013.11.003_bib9","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1056\/NEJMp048023","article-title":"Increasing HDL cholesterol levels","volume":"350","author":"Brewer","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"13","key":"10.1016\/j.cll.2013.11.003_bib10","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJMoa064278","article-title":"HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events","volume":"357","author":"Barter","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.cll.2013.11.003_bib11","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1515\/CCLM.2007.291","article-title":"Calculated low-density lipoprotein cholesterol remains a viable and important test for screening and targeting therapy","volume":"45","author":"Abudu","year":"2007","journal-title":"Clin Chem Lab Med"},{"issue":"4","key":"10.1016\/j.cll.2013.11.003_bib12","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1515\/CCLM.2008.117","article-title":"PROCAM Study: risk prediction for myocardial infarction using microfluidic high-density lipoprotein (HDL) subfractionation is independent of HDL cholesterol","volume":"46","author":"Mueller","year":"2008","journal-title":"Clin Chem Lab Med"},{"issue":"8","key":"10.1016\/j.cll.2013.11.003_bib13","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1515\/CCLM.2006.163","article-title":"The ratio of apoB\/apoAI, apoB and lipoprotein(a) are the best predictors of stable coronary artery disease","volume":"44","author":"Rasouli","year":"2006","journal-title":"Clin Chem Lab Med"},{"issue":"9","key":"10.1016\/j.cll.2013.11.003_bib14","first-page":"921","article-title":"Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update","volume":"169","author":"Genest","year":"2003","journal-title":"CMAJ"},{"issue":"2","key":"10.1016\/j.cll.2013.11.003_bib15","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.cjca.2012.11.032","article-title":"2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult","volume":"29","author":"Anderson","year":"2013","journal-title":"Can J Cardiol"},{"issue":"5","key":"10.1016\/j.cll.2013.11.003_bib16","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1373\/clinchem.2013.203208","article-title":"Beyond LDL cholesterol in assessing cardiovascular risk: apo B or LDL-P?","volume":"59","author":"Master","year":"2013","journal-title":"Clin Chem"},{"issue":"5","key":"10.1016\/j.cll.2013.11.003_bib17","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1373\/clinchem.2012.196733","article-title":"Association of apolipoprotein B and nuclear magnetic resonance spectroscopy-derived LDL particle number with outcomes in 25 clinical studies: assessment by the AACC Lipoprotein and Vascular Diseases Division Working Group on Best Practices","volume":"59","author":"Cole","year":"2013","journal-title":"Clin Chem"},{"issue":"1","key":"10.1016\/j.cll.2013.11.003_bib18","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1373\/clinchem.2011.165712","article-title":"Biomarkers and cardiovascular risk assessment for primary prevention: an update","volume":"58","author":"Gilstrap","year":"2012","journal-title":"Clin Chem"},{"issue":"2","key":"10.1016\/j.cll.2013.11.003_bib19","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1515\/CCLM.2009.037","article-title":"Circulating oxidized low-density lipoprotein: a biomarker of atherosclerosis and cardiovascular risk?","volume":"47","author":"Verhoye","year":"2009","journal-title":"Clin Chem Lab Med"},{"issue":"8","key":"10.1016\/j.cll.2013.11.003_bib20","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1161\/CIRCULATIONAHA.106.683110","article-title":"Benchmarks for the assessment of novel cardiovascular biomarkers","volume":"115","author":"Morrow","year":"2007","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.cll.2013.11.003_bib21","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1373\/clinchem.2011.169839","article-title":"C-reactive protein induces release of both endothelial microparticles and circulating endothelial cells in\u00a0vitro and in\u00a0vivo: further evidence of endothelial dysfunction","volume":"57","author":"Devaraj","year":"2011","journal-title":"Clin Chem"},{"issue":"2","key":"10.1016\/j.cll.2013.11.003_bib22","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1373\/clinchem.2008.109728","article-title":"The clinical utility of high-sensitivity C-reactive protein in cardiovascular disease and the potential implication of JUPITER on current practice guidelines","volume":"55","author":"Mora","year":"2009","journal-title":"Clin Chem"},{"issue":"9","key":"10.1016\/j.cll.2013.11.003_bib23","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1373\/clinchem.2012.188870","article-title":"Clinical utility of lipoprotein-associated phospholipase A(2) for cardiovascular disease prediction in a multiethnic cohort of women","volume":"58","author":"Cook","year":"2012","journal-title":"Clin Chem"},{"issue":"8","key":"10.1016\/j.cll.2013.11.003_bib24","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1373\/49.8.1258","article-title":"Preanalytic and analytic sources of variations in C-reactive protein measurement: implications for cardiovascular disease risk assessment","volume":"49","author":"Ledue","year":"2003","journal-title":"Clin Chem"},{"issue":"1","key":"10.1016\/j.cll.2013.11.003_bib25","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa042378","article-title":"C-reactive protein levels and outcomes after statin therapy","volume":"352","author":"Ridker","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"2A","key":"10.1016\/j.cll.2013.11.003_bib26","doi-asserted-by":"crossref","first-page":"33A","DOI":"10.1016\/j.amjcard.2005.11.014","article-title":"Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)\u2013can C-reactive protein be used to target statin therapy in primary prevention?","volume":"97","author":"Mora","year":"2006","journal-title":"Am J Cardiol"},{"issue":"21","key":"10.1016\/j.cll.2013.11.003_bib27","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.cll.2013.11.003_bib28","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1515\/CCLM.2010.277","article-title":"Inflammatory markers, cholesterol and statins: pathophysiological role and clinical importance","volume":"48","author":"Biasucci","year":"2010","journal-title":"Clin Chem Lab Med"},{"issue":"20","key":"10.1016\/j.cll.2013.11.003_bib29","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1056\/NEJMoa021993","article-title":"Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events","volume":"347","author":"Ridker","year":"2002","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.cll.2013.11.003_bib30","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.jacc.2013.05.016","article-title":"High-sensitivity C-reactive protein and cardiovascular disease: a resolute belief or an elusive link?","volume":"62","author":"Yousuf","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.cll.2013.11.003_bib31","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1373\/clinchem.2008.112334","article-title":"Determinants of the acute-phase protein C-reactive protein in myocardial infarction survivors: the role of comorbidities and environmental factors","volume":"55","author":"Ruckerl","year":"2009","journal-title":"Clin Chem"},{"issue":"2","key":"10.1016\/j.cll.2013.11.003_bib32","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0025-6196(11)60992-0","article-title":"Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: a systematic review","volume":"82","author":"Garza","year":"2007","journal-title":"Mayo Clin Proc"},{"issue":"10","key":"10.1016\/j.cll.2013.11.003_bib33","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1515\/cclm-2012-0015","article-title":"Lipoprotein-associated phospholipase A2 is elevated in patients with severe aortic valve stenosis without clinically overt atherosclerosis","volume":"50","author":"Kolasa-Trela","year":"2012","journal-title":"Clin Chem Lab Med"},{"issue":"5","key":"10.1016\/j.cll.2013.11.003_bib34","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1373\/clinchem.2012.183475","article-title":"Lipoprotein-associated phospholipase A(2) measurements: mass, activity, but little productivity","volume":"58","author":"Stein","year":"2012","journal-title":"Clin Chem"},{"issue":"9725","key":"10.1016\/j.cll.2013.11.003_bib35","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1016\/S0140-6736(10)60319-4","article-title":"Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies","volume":"375","author":"Thompson","year":"2010","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.cll.2013.11.003_bib36","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1021\/tx9003775","article-title":"Myeloperoxidase: an oxidative pathway for generating dysfunctional high-density lipoprotein","volume":"23","author":"Shao","year":"2010","journal-title":"Chem Res Toxicol"},{"issue":"4","key":"10.1016\/j.cll.2013.11.003_bib37","first-page":"384","article-title":"Determination of myeloperoxidase-induced apoAI-apoAII heterodimers in high-density lipoprotein","volume":"42","author":"Kameda","year":"2012","journal-title":"Ann Clin Lab Sci"},{"issue":"23","key":"10.1016\/j.cll.2013.11.003_bib38","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","article-title":"Lipoprotein(a) as a cardiovascular risk factor: current status","volume":"31","author":"Nordestgaard","year":"2010","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.cll.2013.11.003_bib39","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1365-2796.2012.02592.x","article-title":"Lipoprotein(a): resurrected by genetics","volume":"273","author":"Kronenberg","year":"2013","journal-title":"J\u00a0Intern Med"},{"issue":"4","key":"10.1016\/j.cll.2013.11.003_bib40","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality","volume":"302","author":"Erqou","year":"2009","journal-title":"JAMA"},{"issue":"24","key":"10.1016\/j.cll.2013.11.003_bib41","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"Boden","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.cll.2013.11.003_bib42","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1373\/clinchem.2011.170431","article-title":"Genomewide association studies in cardiovascular disease\u2013an update 2011","volume":"58","author":"Zeller","year":"2012","journal-title":"Clin Chem"},{"issue":"5","key":"10.1016\/j.cll.2013.11.003_bib43","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMoa072366","article-title":"Genomewide association analysis of coronary artery disease","volume":"357","author":"Samani","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.cll.2013.11.003_bib44","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.atherosclerosis.2009.06.034","article-title":"Genetic variation at chromosome 1p13.3 affects sortilin mRNA expression, cellular LDL-uptake and serum LDL levels which translates to the risk of coronary artery disease","volume":"208","author":"Linsel-Nitschke","year":"2010","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.cll.2013.11.003_bib45","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.atherosclerosis.2008.06.007","article-title":"Relationship of the ApoE polymorphism to plasma lipid traits among South Asians, Chinese, and Europeans living in Canada","volume":"203","author":"Burman","year":"2009","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.cll.2013.11.003_bib46","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1515\/CCLM.2008.033","article-title":"Association of high sensitive C-reactive protein with apolipoprotein E polymorphism in children and young adults: the Cardiovascular Risk in Young Finns Study","volume":"46","author":"Gronroos","year":"2008","journal-title":"Clin Chem Lab Med"},{"issue":"2","key":"10.1016\/j.cll.2013.11.003_bib47","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.atherosclerosis.2010.04.037","article-title":"ApoE genotype as risk factor in dialysis patients","volume":"212","author":"Chmielewski","year":"2010","journal-title":"Atherosclerosis"},{"issue":"26","key":"10.1016\/j.cll.2013.11.003_bib48","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","article-title":"Genetic variants associated with Lp(a) lipoprotein level and coronary disease","volume":"361","author":"Clarke","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.cll.2013.11.003_bib49","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s11883-013-0310-3","article-title":"Potential of proprotein convertase subtilisin\/kexin type 9 based therapeutics","volume":"15","author":"Stein","year":"2013","journal-title":"Curr Atheroscler Rep"},{"issue":"12","key":"10.1016\/j.cll.2013.11.003_bib50","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1056\/NEJMoa1105803","article-title":"Effect of a monoclonal antibody to PCSK9 on LDL cholesterol","volume":"366","author":"Stein","year":"2012","journal-title":"N\u00a0Engl J Med"}],"container-title":["Clinics in Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272271213000929?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272271213000929?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,6]],"date-time":"2019-08-06T09:40:29Z","timestamp":1565084429000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272271213000929"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["S0272271213000929"],"URL":"https:\/\/doi.org\/10.1016\/j.cll.2013.11.003","relation":{},"ISSN":["0272-2712"],"issn-type":[{"value":"0272-2712","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]}}}